NC525
A Phase 1, Open-Label, Safety, Tolerability, And Efficacy Study of NC525 in Subjects With Advanced Myeloid Neoplasms
More Information
- Trial Status
- Accepting patients
- Trial Phase
- Phase 1
- Enrollment
- 63 patients (estimated)
- Sponsors
- NextCure, Inc.
- Tags
- Monoclonal Antibody, LAIR-1
- Trial Type
- Treatment
- Last Update
- 1 month ago
- SparkCures ID
- 1587
- NCT Identifier
- NCT05787496
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.